Cassy Workman

HLA-B*5701 Screening for Hypersensitivity to Abacavir

S. Mallal, Elizabeth J. Phillips, Giampiero Carosi et al. · New England Journal of Medicine · 2008 · 1.8K citations · Full text

Life Sciences, Dermatology, Immunology +15

Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses

Anthony D. Kelleher, Chad Long, Edward C. Holmes et al. · The Journal of Experimental Medicine · 2001 · 450 citations · Full text

Life Sciences, Immunology, Molecular Biology +15

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Joseph J. Eron, Benjamin Young, David A. Cooper et al. · The Lancet · 2010 · 314 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir

Allison Martin, Don Smith, Andrew Carr et al. · AIDS · 2004 · 299 citations

Pharmacy, Pharmacotherapy, Clinical Pharmacology +15

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

Anthony Mills, Mark Nelson, Dushyantha Jayaweera et al. · AIDS · 2009 · 266 citations

Pharmacy, Pharmacology, Pharmacotherapy +17